吉西他滨联合阿帕替尼治疗晚期胰腺癌的疗效观察

Efficacy and Safety of Gemcitabine in Combination with Apatinib for Advanced Pancreatic Cancer

目的:探讨吉西他滨(Gemcitabine)联合阿帕替尼(Apatinib)治疗晚期胰腺癌的有效性和安全性。方法:回顾性分析经穿刺病理确诊的61例晚期胰腺癌患者,分为观察组(n=30)与对照组(n=31),观察组采取吉西他滨联合阿帕替尼治疗,对照组采取吉西他滨联合替吉奥治疗。观察2组患者近期疗效、不良反应、生存率及中位生存期。结果:观察组治疗后疾病控制率(DCR)明显高于对照组(80.00%vs 56.67%),差异有统计学意义(P<0.05);治疗后2组患者均出现不同程度的不良反应,观察组高血压、蛋白尿、皮疹不良反应多于对照组,对照组贫血、乏力、厌食、恶心/呕吐、腹泻多于观察组,差异有统计学意义(P<0.05);2组6~9个月和10~11个月临床生存率比较,差异无统计学意义(P>0.05);>12个月生存率观察组(43.33%)高于对照组(12.90%),差异有统计学意义(P<0.05);观察组中位生存期10.5个月高于对照组的10.1个月(P<0.05)。COX比例风险模型显示患者中位生存期与肿瘤分期显著相关(P<0.05)。结论:吉西他滨联合阿帕替尼治疗晚期胰腺癌可明显提高晚期胰腺癌患者生存率,疗效较好,且药物安全性好。

Objective:To investigate the efficacy and safety of gemcitabine combined with apatinib in the treatment of advanced pancreatic cancer.Methods:Sixty-one patients with advanced pancreatic cancer diagnosed by pathology admitted were retrospectively analyzed and divided into observation group(n=30)and control group(n=31).The observation group was treated with gemcitabine combined with apatinib,while the control group was treated with gemcitabine combined with tigeol.The short-term efficacy,adverse reactions,survival rates and median survival of the two groups were observed and compared respectively.Results:The DCR of the observation group was significantly higher than that of the control group(80.00%vs 56.67%)after treatment,and the difference between the two groups was significant(P<0.05).After treatment,there were various degrees of adverse reactions in both groups,and there were significant differences in hypertension,proteinuria,anemia,fatigue,anorexia,nausea/vomiting,rash and diarrhea between the two groups(P<0.05).There was no statistical significance in the clinical survival rate between the two groups at 6~9 months and 10~11 months(P>0.05).At 12 months,the observation group was significantly higher than the control group,and the difference between groups was significant(P<0.05).The median survival of 10.5 months in the observation group was significantly higher than 10.1 months in the control group(P<0.05).COX proportional hazards model shows that the median survival of patients is significantly related to tumor stage(P<0.05).Conclusion:Gemcitabine combined with apatinib in the treatment of advanced pancreatic cancer can significantly improve the survival rate of patients with advanced pancreatic cancer,the efficacy is good,and the drug safety is good,worthy of clinical promotion and application.